Trial Profile

A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 01 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 May 2021 Status changed from recruiting to discontinued.
26 Feb 2021 According to a Chimerix media release, 12 patients has been enrolled in second cohort and will update topline data from this second cohort in the second quarter.
25 Feb 2021 According to a Chimerix media release, the second cohort of 12 patients, which is randomized 2:1 and explores a higher dose of DSTAT is now fully enrolled and we look forward to reporting topline data from this cohort in the second quarter.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com